Compare Stocks: BRTX, PLUR, SYBX, and HIND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRTX Biorestorative Therapies	$2.69	$4.39	$2.55 ▼ $34.60	$3.71M	0.83	25,568 shs	17,357 shs
HIND Vyome	$2.10	$2.15	$1.75 ▼ $6.63	$14.74M	1.5	16,142 shs	194,507 shs
PLUR Pluri	$1.08	$1.57	$1.02 ▼ $4.87	$13.34M	0.68	28,802 shs	23,832 shs
SYBX Synlogic	$1.19	$1.08	$0.54 ▼ $1.87	$14.58M	0.5	69,660 shs	61,691 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRTX Biorestorative Therapies	0.00%	+0.75%	-37.53%	-67.11%	-90.72%
HIND Vyome	0.00%	+1.94%	-6.67%	-3.23%	+209,999,900.00%
PLUR Pluri	0.00%	-8.47%	-36.84%	-46.53%	-77.48%
SYBX Synlogic	0.00%	-2.46%	-0.83%	+65.30%	-33.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRTX Biorestorative Therapies	$2.69	$4.39	$2.55 ▼ $34.60	$3.71M	0.83	25,568 shs	17,357 shs
HIND Vyome	$2.10	$2.15	$1.75 ▼ $6.63	$14.74M	1.5	16,142 shs	194,507 shs
PLUR Pluri	$1.08	$1.57	$1.02 ▼ $4.87	$13.34M	0.68	28,802 shs	23,832 shs
SYBX Synlogic	$1.19	$1.08	$0.54 ▼ $1.87	$14.58M	0.5	69,660 shs	61,691 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRTX Biorestorative Therapies	0.00%	+0.75%	-37.53%	-67.11%	-90.72%
HIND Vyome	0.00%	+1.94%	-6.67%	-3.23%	+209,999,900.00%
PLUR Pluri	0.00%	-8.47%	-36.84%	-46.53%	-77.48%
SYBX Synlogic	0.00%	-2.46%	-0.83%	+65.30%	-33.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRTX Biorestorative Therapies	1.00	Sell	N/A	N/A
HIND Vyome	2.50	Moderate Buy	$9.25	340.48% Upside
PLUR Pluri	1.00	Sell	N/A	N/A
SYBX Synlogic	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BRTX, PLUR, SYBX, and HIND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	HIND Vyome	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$3.50
9/3/2026	HIND Vyome	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$3.50
8/26/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/24/2026	BRTX Biorestorative Therapies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/11/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	HIND Vyome	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/23/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/7/2026	PLUR Pluri	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRTX Biorestorative Therapies	$360K	10.31	N/A	N/A	$0.77 per share	3.49
HIND Vyome	$320K	46.07	N/A	N/A	$0.67 per share	3.13
PLUR Pluri	$1.02M	13.08	N/A	N/A	($1.62) per share	-0.67
SYBX Synlogic	$8K	1,822.04	N/A	N/A	$1.09 per share	1.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRTX Biorestorative Therapies	-$14.24M	-$21.40	N/A	N/A	N/A	-3,088.27%	-508.42%	-230.94%	9/22/2026 (Estimated)
HIND Vyome	-$10.26M	-$3.37	N/A	N/A	N/A	-3,024.84%	-197.33%	-138.14%	N/A
PLUR Pluri	-$23.82M	-$2.45	N/A	N/A	N/A	-2,344.59%	N/A	-82.71%	9/23/2026 (Estimated)
SYBX Synlogic	-$23.36M	-$0.06	N/A	N/A	N/A	N/A	-26.47%	-18.00%	11/11/2026 (Estimated)

Latest BRTX, PLUR, SYBX, and HIND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/23/2026	N/A	PLUR Pluri	-$0.66	N/A	N/A	N/A	$0.66 million	N/A
9/22/2026	Q2 2026	BRTX Biorestorative Therapies	-$2.00	N/A	N/A	N/A	$0.60 million	N/A
9/10/2026	Q4 2026	PLUR Pluri	-$0.66	-$0.54	+$0.12	-$0.54	$0.66 million	$0.34 million
8/12/2026	Q2 2026	HIND Vyome	N/A	-$0.10	N/A	-$0.10	N/A	$0.27 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRTX Biorestorative Therapies	N/A	N/A	N/A	N/A	N/A
HIND Vyome	N/A	N/A	N/A	N/A	N/A
PLUR Pluri	N/A	N/A	N/A	N/A	N/A
SYBX Synlogic	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRTX Biorestorative Therapies	N/A	2.35	2.35
HIND Vyome	N/A	4.37	4.37
PLUR Pluri	N/A	0.27	0.27
SYBX Synlogic	N/A	2.65	2.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRTX Biorestorative Therapies	69.38%
HIND Vyome	22.06%
PLUR Pluri	16.59%
SYBX Synlogic	63.40%

Insider Ownership

Company	Insider Ownership
BRTX Biorestorative Therapies	13.60%
HIND Vyome	33.00%
PLUR Pluri	43.16%
SYBX Synlogic	2.62%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRTX Biorestorative Therapies	14	1.38 million	1.19 million	Not Optionable
HIND Vyome	18	7.02 million	4.70 million	N/A
PLUR Pluri	113	12.35 million	7.02 million	No Data
SYBX Synlogic	80	12.25 million	11.39 million	No Data

BRTX, PLUR, SYBX, and HIND Headlines

Recent News About These Companies

Reviewing Synlogic (NASDAQ:SYBX) and Oncobiologics (NASDAQ:OTLK)

September 16, 2026 | defenseworld.netD

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Varex Imaging Corporation (Nasdaq – VREX), Synlogic, Inc. (OTC – SYBX), Bowman Consulting Group Ltd. (Nasdaq – BWMN), Nathan's Famous, Inc. (Nasdaq – NATH)

August 28, 2026 | globenewswire.com

SYBX Stock Alert: Halper Sadeh LLC is Investigating Whether Synlogic, Inc. is Obtaining a Fair Price for its Shareholders

August 10, 2026 | tmcnet.com

Synlogic and Caldera Therapeutics announce merger and $278 million private placement

July 29, 2026 | msn.com

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

July 29, 2026 | aol.comA

Synlogic's Strategic Crossroads: A Company in Limbo

February 10, 2026 | aktiencheck.deA

Synlogic Challenges Nasdaq Delisting Notice

November 26, 2025 | tipranks.com

We Think Synlogic (NASDAQ:SYBX) Can Afford To Drive Business Growth

September 18, 2025 | uk.finance.yahoo.com

Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance

June 28, 2025 | finance.yahoo.com

Synlogic's executive sells shares worth $2,802

February 5, 2025 | msn.com

Synlogic Reports Q3 2024 Financial Outcomes

November 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results

November 13, 2024 | finanznachrichten.de

Synlogic Reports Third Quarter 2024 Financial Results

November 12, 2024 | globenewswire.com

Synlogic preps phenylketonuria drug for phase 3 after mid-stage win

November 6, 2024 | pharmaphorum.comP

Synlogic, Inc. (0A8U.L)

August 24, 2024 | nz.finance.yahoo.com

MIN.SG,0P0001I7V6,0 (MIN.SG)

August 16, 2024 | nz.finance.yahoo.com

Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty

August 14, 2024 | markets.businessinsider.com

Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | finanznachrichten.de

SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024

August 8, 2024 | investorplace.com

Synlogic Reports Second Quarter 2024 Financial Results

August 8, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX, PLUR, SYBX, and HIND Company Descriptions

Biorestorative Therapies NASDAQ:BRTX

$2.69 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.80 +0.11 (+3.90%)

As of 09/18/2026 07:57 PM Eastern

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. The company was incorporated in 1997 and is based in Melville, New York.

Vyome NASDAQ:HIND

$2.10 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.01 -0.09 (-4.10%)

As of 09/18/2026 07:22 PM Eastern

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Pluri NASDAQ:PLUR

$1.08 0.00 (0.00%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.02 -0.06 (-5.09%)

As of 09/18/2026 07:00 PM Eastern

Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Synlogic NASDAQ:SYBX

$1.19 0.00 (0.00%)

As of 09/18/2026 03:47 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRTX, PLUR, SYBX, and HIND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRTX, PLUR, SYBX, and HIND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRTX, PLUR, SYBX, and HIND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX, PLUR, SYBX, and HIND Company Descriptions

Biorestorative Therapies NASDAQ:BRTX

Vyome NASDAQ:HIND

Pluri NASDAQ:PLUR

Synlogic NASDAQ:SYBX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BRTX, PLUR, SYBX, and HIND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BRTX, PLUR, SYBX, and HIND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BRTX, PLUR, SYBX, and HIND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX, PLUR, SYBX, and HIND Company Descriptions

Biorestorative Therapies NASDAQ:BRTX

Vyome NASDAQ:HIND

Pluri NASDAQ:PLUR

Synlogic NASDAQ:SYBX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools